107.346 articles found

VISUAL HALLUCINATIONS IN PARKINSON’ S DISEASE WERE ASSOCIATED WITH DECREASING BLOOD FLOW IN THE BILATERAL POSTERIOR CINGULATE CORTEX ON 123I-IMP-SPECT

Check source for author details

The international journal of neuropsychopharmacology · 2025-02-01

The "Wearing Off" Phenomenon for Rasagiline, Entacapone, Carbidopa, and Levodopa in the Setting of Parkinson's Disease.

Cromwell R, Um T.

HCA Healthc J Med · 2025-02-01

DOI: 10.36518/2689-0216.1718PMID: 40071188

The impact of an active lifestyle on markers of intestinal inflammation in Parkinson's disease: Preliminary findings.

Chtioui N, Duval C, St-Pierre DH.

Clin Park Relat Disord · 2025-02-01

DOI: 10.1016/j.prdoa.2025.100301PMID: 40093191

Visual hallucinations in Parkinson's disease: spotlight on central cholinergic dysfunction.

Ignatavicius A, Matar E, Lewis SJG.

Brain · 2025-02-01

DOI: 10.1093/brain/awae289PMID: 39252645

Skin adhesion of a newly developed, bioequivalent rotigotine patch formulation in comparison to the originator product: Results of a multi-center, randomized, crossover trial in patients with Parkinson's disease.

Jost WH, Wang M, Wauer G, Dax A, Wedemeyer RS, Schug B, Warnke A, Leblanc A, Schurad B.

Int J Clin Pharmacol Ther · 2025-02-01

DOI: 10.5414/cp204672PMID: 39370808

Power of Multi-Modality Variables in Predicting Parkinson's Disease Progression.

Jiang Y, Yang HJ, Kim J, Tang Z, Ruan X.

IEEE J Biomed Health Inform · 2025-02-01

DOI: 10.1109/jbhi.2024.3482180PMID: 39446537

Proceedings of the 18th annual meeting of the Genetic Epidemiology of Parkinson's disease consortium.

Crosiers D, Markopoulou K, GEoPD steering committee.

Acta Neurol Belg · 2025-02-01

DOI: 10.1007/s13760-024-02651-5PMID: 39570493

Measurement of Physical Activity Divided Into Inside and Outside the Home in People With Parkinson's Disease: A Feasibility Study.

Hirakawa Y, Sakurai H, Takeda K, Koyama S, Iwai M, Motoya I, Kanada Y, Kawamura N, Kawamura M, Tanabe S.

J Eval Clin Pract · 2025-02-01

DOI: 10.1111/jep.14251PMID: 39601667

Altered Nigral Amide Proton Transfer Imaging Signal Concordant With Motor Asymmetry in Parkinson's Disease: A Multipool CEST MRI Study.

Tian Y, Li X, Chen H, Su W, Li S, Zheng D, Li C, Chen M.

NMR Biomed · 2025-02-01

DOI: 10.1002/nbm.5310PMID: 39726050

Using a sex- and gender-informed lens to enhance care in Parkinson's disease.

Castro-Aldrete L, Huc M, Domingos J, Vaudano E, Klietz M, Trenkwalder C, Oosterbaan A, Flanagan R, Marongiu R, Santuccione-Chadha A.

Nat Med · 2025-02-01

DOI: 10.1038/s41591-024-03363-2PMID: 39753966

An Acetylcholine M1 Receptor-Positive Allosteric Modulator (TAK-071) in Parkinson Disease With Cognitive Impairment: A Phase 2 Randomized Clinical Trial.

Shanbhag NM, Padmanabhan JL, Zhang Z, Harel BT, Jia H, Kangarloo T, Yin W, Dowling AV, Laurenza A, Khudyakov P, Galinsky K, Latzman RD, Simuni T, Weintraub D, Horak FB, Lustig C, Maruff P, Simen AA.

JAMA Neurol · 2025-02-01

DOI: 10.1001/jamaneurol.2024.4519PMID: 39761063

HDAC4/5 Inhibitor, LMK-235 Improves Animal Voluntary Movement in MPTP-Induced Parkinson's Disease Model.

Lee H, Kim HJ, Min JS, Lee E, Choi DK, Choi JH, Seo Y, Lee S, Im CY, Bae GH, Oh Y, Ko EA, Jung SC, Kim SH, Kwon OB.

Pharmacol Res Perspect · 2025-02-01

DOI: 10.1002/prp2.70057PMID: 39806528